Keeping You Informed | Biologics & Biosimilars
Monday, May 27, 2019Understand the transition from biologic to biosimilar medications with Pacific Blue Cross. Learn about the benefits, process, and how biosimilars can be a cost-effective alternative for your treatment.
On May 27th, 2019, the Government of British Columbia and BC PharmaCare announced the expansion of the use of biosimilars to create new opportunities for new drug listings. Coverage for the original biologic (originator) drugs Remicade®, Enbrel® and Lantus® will be discontinued for affected patients, and coverage will instead be provided for their biosimilar.
Find out more information about biosimilars, including a list of frequently asked questions, by visiting www.gov.bc.ca/biosimilars
For more details, please log-in to your Member Profile